20/20 Biolabs, Inc. (AIDX)
NASDAQ:AIDX
Want to see AIDX full AI Analyst Report?
AIDX Stock Chart & Stats
$1.78
--
Market closed
$1.78
--
Day’s Range― - ―
52-Week Range$1.45 - $50.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.72
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,480,089
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1.74Price Target Upside-2.38% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AIDX FAQ
What was 20/20 Biolabs, Inc.’s price range in the past 12 months?
20/20 Biolabs, Inc. lowest stock price was $1.45 and its highest was $50.00 in the past 12 months.
What is 20/20 Biolabs, Inc.’s market cap?
Currently, no data Available
When is 20/20 Biolabs, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 20/20 Biolabs, Inc.’s earnings last quarter?
Currently, no data Available
Is 20/20 Biolabs, Inc. overvalued?
According to Wall Street analysts 20/20 Biolabs, Inc.’s price is currently Overvalued.
Does 20/20 Biolabs, Inc. pay dividends?
20/20 Biolabs, Inc. does not currently pay dividends.
What is 20/20 Biolabs, Inc.’s EPS estimate?
20/20 Biolabs, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 20/20 Biolabs, Inc. have?
20/20 Biolabs, Inc. has 10,480,089 shares outstanding.
What happened to 20/20 Biolabs, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 20/20 Biolabs, Inc.?
Currently, no hedge funds are holding shares in AIDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
20/20 Biolabs, Inc.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
AIDX Stock 12 Month Forecast
Average Price Target
$1.74
▼(-2.38% Downside)
Ownership Overview
0.50% Insiders
<0.01% Other Institutional Investors
99.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---